Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

[Medical care data as the basis for evidence-based health care politics].

Cornelius F, Lindemann L, Schroeder A, Schulze M.

Urologe A. 2019 Aug;58(8):910-917. doi: 10.1007/s00120-019-0980-8. Review. German.

PMID:
31240373
2.

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Berry-Kravis EM, Lindemann L, Jønch AE, Apostol G, Bear MF, Carpenter RL, Crawley JN, Curie A, Des Portes V, Hossain F, Gasparini F, Gomez-Mancilla B, Hessl D, Loth E, Scharf SH, Wang PP, Von Raison F, Hagerman R, Spooren W, Jacquemont S.

Nat Rev Drug Discov. 2018 Apr;17(4):280-299. doi: 10.1038/nrd.2017.221. Epub 2017 Dec 8. Review.

PMID:
29217836
3.

mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex.

Kelly E, Schaeffer SM, Dhamne SC, Lipton JO, Lindemann L, Honer M, Jaeschke G, Super CE, Lammers SH, Modi ME, Silverman JL, Dreier JR, Kwiatkowski DJ, Rotenberg A, Sahin M.

Neuropsychopharmacology. 2018 May;43(6):1457-1465. doi: 10.1038/npp.2017.295. Epub 2017 Dec 5.

4.

Results and evaluation of a first-in-human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods.

Sturm S, Delporte ML, Hadi S, Schobel S, Lindemann L, Weikert R, Jaeschke G, Derks M, Palermo G.

Br J Clin Pharmacol. 2018 Mar;84(3):445-455. doi: 10.1111/bcp.13466. Epub 2017 Dec 18.

5.

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.

Youssef EA, Berry-Kravis E, Czech C, Hagerman RJ, Hessl D, Wong CY, Rabbia M, Deptula D, John A, Kinch R, Drewitt P, Lindemann L, Marcinowski M, Langland R, Horn C, Fontoura P, Santarelli L, Quiroz JA; FragXis Study Group.

Neuropsychopharmacology. 2018 Feb;43(3):503-512. doi: 10.1038/npp.2017.177. Epub 2017 Aug 17.

6.

[Health policy 2018-there's always the next reform].

Lindemann LF.

Urologe A. 2017 Aug;56(8):983-984. doi: 10.1007/s00120-017-0451-z. Review. German. No abstract available.

PMID:
28698961
7.

Temperature and concentration calibration of aqueous polyvinylpyrrolidone (PVP) solutions for isotropic diffusion MRI phantoms.

Wagner F, Laun FB, Kuder TA, Mlynarska A, Maier F, Faust J, Demberg K, Lindemann L, Rivkin B, Nagel AM, Ladd ME, Maier-Hein K, Bickelhaupt S, Bach M.

PLoS One. 2017 Jun 19;12(6):e0179276. doi: 10.1371/journal.pone.0179276. eCollection 2017.

8.

Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia.

Steullet P, Cabungcal JH, Coyle J, Didriksen M, Gill K, Grace AA, Hensch TK, LaMantia AS, Lindemann L, Maynard TM, Meyer U, Morishita H, O'Donnell P, Puhl M, Cuenod M, Do KQ.

Mol Psychiatry. 2017 Jul;22(7):936-943. doi: 10.1038/mp.2017.47. Epub 2017 Mar 21.

9.

Blocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences.

Peterlik D, Stangl C, Bauer A, Bludau A, Keller J, Grabski D, Killian T, Schmidt D, Zajicek F, Jaeschke G, Lindemann L, Reber SO, Flor PJ, Uschold-Schmidt N.

Brain Behav Immun. 2017 Jan;59:79-92. doi: 10.1016/j.bbi.2016.08.007. Epub 2016 Aug 11.

PMID:
27524668
10.

[Anticorruption law in health care].

Lindemann LF.

Urologe A. 2016 Aug;55(8):1033-5. doi: 10.1007/s00120-016-0180-8. German. No abstract available.

PMID:
27411991
11.

Metabotropic glutamate receptor signaling is required for NMDA receptor-dependent ocular dominance plasticity and LTD in visual cortex.

Sidorov MS, Kaplan ES, Osterweil EK, Lindemann L, Bear MF.

Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12852-7. doi: 10.1073/pnas.1512878112. Epub 2015 Sep 28.

12.

[Founded out of protest, committed to consensus, and determined].

Lindemann L.

Urologe A. 2015 Aug;54(8):1092-3. doi: 10.1007/s00120-015-3887-z. German. No abstract available.

PMID:
26246204
13.

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.

Lindemann L, Porter RH, Scharf SH, Kuennecke B, Bruns A, von Kienlin M, Harrison AC, Paehler A, Funk C, Gloge A, Schneider M, Parrott NJ, Polonchuk L, Niederhauser U, Morairty SR, Kilduff TS, Vieira E, Kolczewski S, Wichmann J, Hartung T, Honer M, Borroni E, Moreau JL, Prinssen E, Spooren W, Wettstein JG, Jaeschke G.

J Pharmacol Exp Ther. 2015 Apr;353(1):213-33. doi: 10.1124/jpet.114.222463. Epub 2015 Feb 9.

PMID:
25665805
14.

Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion.

Tian D, Stoppel LJ, Heynen AJ, Lindemann L, Jaeschke G, Mills AA, Bear MF.

Nat Neurosci. 2015 Feb;18(2):182-4. doi: 10.1038/nn.3911. Epub 2015 Jan 12.

15.

Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.

Jaeschke G, Kolczewski S, Spooren W, Vieira E, Bitter-Stoll N, Boissin P, Borroni E, Büttelmann B, Ceccarelli S, Clemann N, David B, Funk C, Guba W, Harrison A, Hartung T, Honer M, Huwyler J, Kuratli M, Niederhauser U, Pähler A, Peters JU, Petersen A, Prinssen E, Ricci A, Rueher D, Rueher M, Schneider M, Spurr P, Stoll T, Tännler D, Wichmann J, Porter RH, Wettstein JG, Lindemann L.

J Med Chem. 2015 Feb 12;58(3):1358-71. doi: 10.1021/jm501642c. Epub 2015 Feb 2.

PMID:
25565255
16.

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.

Scharf SH, Jaeschke G, Wettstein JG, Lindemann L.

Curr Opin Pharmacol. 2015 Feb;20:124-34. doi: 10.1016/j.coph.2014.11.004. Epub 2014 Dec 2. Review.

PMID:
25488569
17.

Homer1/mGluR5 activity moderates vulnerability to chronic social stress.

Wagner KV, Hartmann J, Labermaier C, Häusl AS, Zhao G, Harbich D, Schmid B, Wang XD, Santarelli S, Kohl C, Gassen NC, Matosin N, Schieven M, Webhofer C, Turck CW, Lindemann L, Jaschke G, Wettstein JG, Rein T, Müller MB, Schmidt MV.

Neuropsychopharmacology. 2015 Mar 13;40(5):1222-33. doi: 10.1038/npp.2014.308.

18.

Drug discovery for autism spectrum disorder: challenges and opportunities.

Ghosh A, Michalon A, Lindemann L, Fontoura P, Santarelli L.

Nat Rev Drug Discov. 2013 Oct;12(10):777-90. doi: 10.1038/nrd4102. Review.

PMID:
24080699
19.

Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.

Michalon A, Bruns A, Risterucci C, Honer M, Ballard TM, Ozmen L, Jaeschke G, Wettstein JG, von Kienlin M, Künnecke B, Lindemann L.

Biol Psychiatry. 2014 Feb 1;75(3):189-97. doi: 10.1016/j.biopsych.2013.05.038. Epub 2013 Jul 30.

PMID:
23910948
20.

The impact of Bdnf gene deficiency to the memory impairment and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer's disease.

Rantamäki T, Kemppainen S, Autio H, Stavén S, Koivisto H, Kojima M, Antila H, Miettinen PO, Kärkkäinen E, Karpova N, Vesa L, Lindemann L, Hoener MC, Tanila H, Castrén E.

PLoS One. 2013 Jul 3;8(7):e68722. doi: 10.1371/journal.pone.0068722. Print 2013.

21.

Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination.

Barnes N, van Noord JA, Brindicci C, Lindemann L, Varoli G, Perpiña M, Guastalla D, Casula D, Patel S, Chanez P; FACTO (Foster® As Complete Treatment Option) Study Group.

Pulm Pharmacol Ther. 2013 Oct;26(5):555-61. doi: 10.1016/j.pupt.2013.01.011. Epub 2013 Mar 22.

PMID:
23524015
22.

Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse.

Higashimori H, Morel L, Huth J, Lindemann L, Dulla C, Taylor A, Freeman M, Yang Y.

Hum Mol Genet. 2013 May 15;22(10):2041-54. doi: 10.1093/hmg/ddt055. Epub 2013 Feb 7.

23.

Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders.

Spooren W, Lindemann L, Ghosh A, Santarelli L.

Trends Pharmacol Sci. 2012 Dec;33(12):669-84. doi: 10.1016/j.tips.2012.09.004. Epub 2012 Oct 18. Review.

PMID:
23084458
24.

Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7.

Ullmer C, Zoffmann S, Bohrmann B, Matile H, Lindemann L, Flor P, Malherbe P.

Br J Pharmacol. 2012 Dec;167(7):1448-66. doi: 10.1111/j.1476-5381.2012.02090.x.

25.

Differential effects of diazepam and MPEP on habituation and neuro-behavioural processes in inbred mice.

Salomons AR, Pinzon NE, Boleij H, Kirchhoff S, Arndt SS, Nordquist RE, Lindemann L, Jaeschke G, Spooren W, Ohl F.

Behav Brain Funct. 2012 Jun 11;8:30. doi: 10.1186/1744-9081-8-30.

26.

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L.

Neuron. 2012 Apr 12;74(1):49-56. doi: 10.1016/j.neuron.2012.03.009.

27.

Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996-2010.

Enders G, Daiminger A, Lindemann L, Knotek F, Bäder U, Exler S, Enders M.

Med Microbiol Immunol. 2012 Aug;201(3):303-9. doi: 10.1007/s00430-012-0232-7. Epub 2012 Mar 8.

PMID:
22398714
28.

The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice.

Lindholm JS, Autio H, Vesa L, Antila H, Lindemann L, Hoener MC, Skolnick P, Rantamäki T, Castrén E.

Neuropharmacology. 2012 Jan;62(1):391-7. doi: 10.1016/j.neuropharm.2011.08.015. Epub 2011 Aug 16.

PMID:
21867718
29.

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.

Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, Porter R, Hartung T, Kolczewski S, Büttelmann B, Flament C, Diener C, Fischer C, Gatti S, Prinssen EP, Parrott N, Hoffmann G, Wettstein JG.

J Pharmacol Exp Ther. 2011 Nov;339(2):474-86. doi: 10.1124/jpet.111.185660. Epub 2011 Aug 17.

PMID:
21849627
30.

Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus.

Autio H, Mätlik K, Rantamäki T, Lindemann L, Hoener MC, Chao M, Arumäe U, Castrén E.

Neuropharmacology. 2011 Dec;61(8):1291-6. doi: 10.1016/j.neuropharm.2011.07.033. Epub 2011 Jul 30.

31.

G protein-coupled receptor transmembrane binding pockets and their applications in GPCR research and drug discovery: a survey.

Kratochwil NA, Gatti-McArthur S, Hoener MC, Lindemann L, Christ AD, Green LG, Guba W, Martin RE, Malherbe P, Porter RH, Slack JP, Winnig M, Dehmlow H, Grether U, Hertel C, Narquizian R, Panousis CG, Kolczewski S, Steward L.

Curr Top Med Chem. 2011;11(15):1902-24.

PMID:
21470172
32.

Darkness reduces BDNF expression in the visual cortex and induces repressive chromatin remodeling at the BDNF gene in both hippocampus and visual cortex.

Karpova NN, Rantamäki T, Di Lieto A, Lindemann L, Hoener MC, Castrén E.

Cell Mol Neurobiol. 2010 Oct;30(7):1117-23. doi: 10.1007/s10571-010-9544-6. Epub 2010 Jul 8.

PMID:
20614233
33.

In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite.

Lindemann L, Jacobsen H, Schuhbauer D, Knoflach F, Gatti S, Wettstein JG, Loetscher H, Chu T, Ebeling M, Paulson JC, Prinssen E, Brockhaus M.

Eur J Pharmacol. 2010 Feb 25;628(1-3):6-10. doi: 10.1016/j.ejphar.2009.11.020. Epub 2009 Nov 14.

34.

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.

Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, Dutkowski R, Hoffmann G, Breidenbach A, Lindemann L, Carey E, Boak L, Gieschke R, Sacks S, Solsky J, Small I, Reddy D.

Drug Saf. 2008;31(12):1097-114. doi: 10.2165/0002018-200831120-00006. Review.

PMID:
19026027
35.

Trace amine-associated receptor 1 modulates dopaminergic activity.

Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, Bettler B, Wettstein JG, Borroni E, Moreau JL, Hoener MC.

J Pharmacol Exp Ther. 2008 Mar;324(3):948-56. Epub 2007 Dec 14.

PMID:
18083911
36.

Salivary flow rate, pH, and concentrations of calcium, phosphate, and sIgA in Brazilian pregnant and non-pregnant women.

Rockenbach MI, Marinho SA, Veeck EB, Lindemann L, Shinkai RS.

Head Face Med. 2006 Nov 28;2:44.

37.

An automated system for the analysis of G protein-coupled receptor transmembrane binding pockets: alignment, receptor-based pharmacophores, and their application.

Kratochwil NA, Malherbe P, Lindemann L, Ebeling M, Hoener MC, Mühlemann A, Porter RH, Stahl M, Gerber PR.

J Chem Inf Model. 2005 Sep-Oct;45(5):1324-36.

PMID:
16180909
38.

A renaissance in trace amines inspired by a novel GPCR family.

Lindemann L, Hoener MC.

Trends Pharmacol Sci. 2005 May;26(5):274-81. Review.

PMID:
15860375
39.

Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors.

Lindemann L, Ebeling M, Kratochwil NA, Bunzow JR, Grandy DK, Hoener MC.

Genomics. 2005 Mar;85(3):372-85.

PMID:
15718104
40.

Cre recombinase specificity defined by the tau locus.

Korets-Smith E, Lindemann L, Tucker KL, Jiang C, Kabacs N, Belteki G, Haigh J, Gertsenstein M, Nagy A.

Genesis. 2004 Nov;40(3):131-8.

PMID:
15493019
41.
42.

Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome.

Enders G, Bäder U, Lindemann L, Schalasta G, Daiminger A.

Prenat Diagn. 2001 May;21(5):362-77. Erratum in: Prenat Diagn 2001 Jul;21(7):605.

PMID:
11360277
43.

SAF-B protein couples transcription and pre-mRNA splicing to SAR/MAR elements.

Nayler O, Strätling W, Bourquin JP, Stagljar I, Lindemann L, Jasper H, Hartmann AM, Fackelmayer FO, Ullrich A, Stamm S.

Nucleic Acids Res. 1998 Aug 1;26(15):3542-9.

44.

[Hearing in a geriatric perspective].

Boisen G, Lindemann L, Lange K, Horwitz N, Parving A.

Ugeskr Laeger. 1997 Oct 20;159(43):6362-6. Danish.

PMID:
9411959
45.

The use and benefit of in-the-ear hearing aids. A four-year follow-up examination.

Henrichsen J, Noring E, Lindemann L, Christensen B, Parving A.

Scand Audiol. 1991;20(1):55-9.

PMID:
1842270
46.

[Keeping pets--how dangerous is it?].

Enders G, Biber M, Lindemann L.

Gynakologe. 1987 Jun;20(2):99-105. German. No abstract available.

PMID:
3623257
47.

[Effect, tolerance and dose dependence of salbutamol powder inhalations].

Nakhosteen JA, Lindemann L, Hirche H.

Med Welt. 1983 Nov 4;34(44):1254-7. German. No abstract available.

PMID:
6358772
48.

[Bronchofiberscopic catheter and flexible needle suction biopsies in extraluminal and peripheral lung lesion].

Nakhosteen JA, Lindemann L, Orth U, Heye M.

Prax Klin Pneumol. 1983 Oct;37 Suppl 1:854-5. German. No abstract available.

PMID:
6647355
49.
50.

[Mucociliary clearance. Results in smokers, nonsmokers and patients with with respiratory tract diseases].

Nakhosteen JA, Lindemann L, Vieira J.

Dtsch Med Wochenschr. 1982 Nov 12;107(45):1713-6. German.

PMID:
7140550

Supplemental Content

Loading ...
Support Center